PE20170245A1 - Pirazinas moduladoras de gpr 6 - Google Patents
Pirazinas moduladoras de gpr 6Info
- Publication number
- PE20170245A1 PE20170245A1 PE2016001477A PE2016001477A PE20170245A1 PE 20170245 A1 PE20170245 A1 PE 20170245A1 PE 2016001477 A PE2016001477 A PE 2016001477A PE 2016001477 A PE2016001477 A PE 2016001477A PE 20170245 A1 PE20170245 A1 PE 20170245A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- cycloalkyl
- optionally substituted
- pirazines
- gpr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
- C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461940294P | 2014-02-14 | 2014-02-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20170245A1 true PE20170245A1 (es) | 2017-03-30 |
Family
ID=52598823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016001477A PE20170245A1 (es) | 2014-02-14 | 2015-02-13 | Pirazinas moduladoras de gpr 6 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US10000468B2 (https=) |
| EP (1) | EP3105216B1 (https=) |
| JP (1) | JP6484640B2 (https=) |
| KR (1) | KR20160122215A (https=) |
| CN (1) | CN106103421B (https=) |
| AU (1) | AU2015218402B2 (https=) |
| BR (1) | BR112016018418A2 (https=) |
| CA (1) | CA2939382A1 (https=) |
| CL (1) | CL2016002043A1 (https=) |
| CR (1) | CR20160428A (https=) |
| DO (1) | DOP2016000211A (https=) |
| EA (1) | EA033861B1 (https=) |
| EC (1) | ECSP16074207A (https=) |
| ES (1) | ES2702205T3 (https=) |
| GE (2) | GEP20186893B (https=) |
| IL (1) | IL247140B (https=) |
| MA (1) | MA39337B1 (https=) |
| MX (1) | MX369857B (https=) |
| MY (1) | MY184366A (https=) |
| PE (1) | PE20170245A1 (https=) |
| PH (1) | PH12016501613B1 (https=) |
| UA (1) | UA117779C2 (https=) |
| WO (1) | WO2015123533A1 (https=) |
| ZA (1) | ZA201606077B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20160122215A (ko) * | 2014-02-14 | 2016-10-21 | 다케다 야쿠힌 고교 가부시키가이샤 | Gpr6의 피라진 조절제 |
| EA202092441A1 (ru) | 2016-06-07 | 2021-05-21 | Джакобио Фармасьютикалс Ко., Лтд. | Новые гетероциклические производные, применимые в качестве ингибиторов shp2 |
| KR20240026521A (ko) | 2017-03-23 | 2024-02-28 | 자코바이오 파마슈티칼스 컴퍼니 리미티드 | Shp2 억제제로서 유용한 신규한 헤테로환형 유도체 |
| MX390512B (es) * | 2017-03-26 | 2025-03-20 | Takeda Pharmaceuticals Co | Carboxamidas heteroaromáticas sustituidas con piperidinilo y piperazinilo como moduladores de gpr6. |
| JOP20180057A1 (ar) * | 2017-06-15 | 2019-01-30 | Takeda Pharmaceuticals Co | مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6 |
| CN112839935A (zh) | 2018-09-26 | 2021-05-25 | 北京加科思新药研发有限公司 | 可用作shp2抑制剂的新型杂环衍生物 |
| CN115996908B (zh) * | 2020-04-30 | 2026-04-24 | 俄勒冈健康科学大学 | Gpr39蛋白的拮抗剂 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4159331A (en) * | 1978-05-05 | 1979-06-26 | The Upjohn Company | Antihypertensive 4-aminoquinolines |
| US5563142A (en) * | 1989-12-28 | 1996-10-08 | The Upjohn Company | Diaromatic substituted compounds as anti-HIV-1 agents |
| AU6453501A (en) * | 1999-02-26 | 2001-09-03 | Arena Pharmaceuticals, Inc. | Small molecule modulators of G protein-coupled receptor six |
| US6774138B2 (en) | 1999-08-31 | 2004-08-10 | Merck & Co., Inc. | Thiazolyl(pyridyl)ethyne compounds |
| CN1231473C (zh) | 2000-02-16 | 2005-12-14 | 神经能质公司 | 取代的芳基吡嗪 |
| PT1397351E (pt) | 2001-06-01 | 2010-01-04 | Hoffmann La Roche | Derivados de pirimidina, triazina e pirazina como receptores de glutamato |
| US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| ES2306859T3 (es) | 2002-03-13 | 2008-11-16 | Janssen Pharmaceutica Nv | Derivados de sulfonil como nuevos inhibidores de histona deacetilasa. |
| JPWO2004054617A1 (ja) * | 2002-12-13 | 2006-04-20 | 協和醗酵工業株式会社 | 中枢疾患の予防および／または治療剤 |
| CN1829701A (zh) | 2003-07-30 | 2006-09-06 | 泽农医药公司 | 哌嗪衍生物和它们作为治疗剂的用途 |
| US20050070718A1 (en) * | 2003-09-30 | 2005-03-31 | Abbott Gmbh & Co. Kg | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them |
| US8580842B2 (en) * | 2003-09-30 | 2013-11-12 | Abbott Gmbh & Co. Kg | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them |
| EP1715867A4 (en) * | 2004-02-12 | 2009-04-15 | Merck & Co Inc | BIPYRIDYLAMIDE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 |
| ATE458730T1 (de) | 2004-04-13 | 2010-03-15 | Icagen Inc | Polycyclische pyrazine als kaliumionenkanal- modulatoren |
| GB0414438D0 (en) * | 2004-06-28 | 2004-07-28 | Syngenta Participations Ag | Chemical compounds |
| US20060199828A1 (en) * | 2005-03-04 | 2006-09-07 | Georg Jaeschke | Pyrazine-2-carboxyamide derivatives |
| US20060258672A1 (en) | 2005-05-13 | 2006-11-16 | Joseph Barbosa | Multicyclic compounds and methods of their use |
| WO2007044085A2 (en) | 2005-05-19 | 2007-04-19 | Xenon Pharmaceuticals Inc. | Heteroaryl compounds and their uses as therapeutic agents |
| US8495335B2 (en) * | 2006-06-16 | 2013-07-23 | Raytheon Company | Data translation system and method |
| MX2010013876A (es) | 2008-06-20 | 2011-03-04 | Metabolex Inc | Agonistas de arilo grpr119 y sus usos . |
| DK2563776T3 (en) | 2010-04-27 | 2016-09-19 | Calcimedica Inc | Relations that modulate intracellular calcium |
| CA2798325A1 (en) | 2010-05-13 | 2011-11-17 | Amgen Inc. | Heteroaryloxyheterocyclyl compounds as pde10 inhibitors |
| MA34300B1 (fr) * | 2010-05-13 | 2013-06-01 | Amgen Inc | Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10 |
| US20120184572A1 (en) | 2011-01-13 | 2012-07-19 | Metabolex, Inc. | Aryl gpr119 agonists and uses thereof |
| WO2013063458A2 (en) * | 2011-10-27 | 2013-05-02 | Mayo Foundation For Medical Education And Research | Inhibiting g protein coupled receptor 6 kinase polypeptides |
| WO2014028479A1 (en) * | 2012-08-13 | 2014-02-20 | Envoy Therapeutics, Inc. | Quinoxaline derivatives as gpr6 modulators |
| BR112016008632A8 (pt) | 2013-10-21 | 2020-03-17 | Merck Patent Gmbh | compostos de heteroarila como inibidores de btk, seus usos, e composição farmacêutica |
| KR20160122215A (ko) * | 2014-02-14 | 2016-10-21 | 다케다 야쿠힌 고교 가부시키가이샤 | Gpr6의 피라진 조절제 |
-
2015
- 2015-02-13 KR KR1020167025131A patent/KR20160122215A/ko not_active Ceased
- 2015-02-13 MA MA39337A patent/MA39337B1/fr unknown
- 2015-02-13 EA EA201691632A patent/EA033861B1/ru unknown
- 2015-02-13 GE GEAP201514266A patent/GEP20186893B/en unknown
- 2015-02-13 BR BR112016018418A patent/BR112016018418A2/pt not_active Application Discontinuation
- 2015-02-13 UA UAA201609102A patent/UA117779C2/uk unknown
- 2015-02-13 AU AU2015218402A patent/AU2015218402B2/en active Active
- 2015-02-13 CA CA2939382A patent/CA2939382A1/en not_active Abandoned
- 2015-02-13 PE PE2016001477A patent/PE20170245A1/es unknown
- 2015-02-13 US US15/118,461 patent/US10000468B2/en not_active Expired - Fee Related
- 2015-02-13 EP EP15707836.1A patent/EP3105216B1/en active Active
- 2015-02-13 MX MX2016010529A patent/MX369857B/es active IP Right Grant
- 2015-02-13 CN CN201580013589.1A patent/CN106103421B/zh active Active
- 2015-02-13 WO PCT/US2015/015841 patent/WO2015123533A1/en not_active Ceased
- 2015-02-13 GE GEAP201814266A patent/GEAP201814266A/en unknown
- 2015-02-13 CR CR20160428A patent/CR20160428A/es unknown
- 2015-02-13 JP JP2016551806A patent/JP6484640B2/ja not_active Expired - Fee Related
- 2015-02-13 MY MYPI2016702927A patent/MY184366A/en unknown
- 2015-02-13 ES ES15707836T patent/ES2702205T3/es active Active
-
2016
- 2016-08-07 IL IL247140A patent/IL247140B/en active IP Right Grant
- 2016-08-12 DO DO2016000211A patent/DOP2016000211A/es unknown
- 2016-08-12 PH PH12016501613A patent/PH12016501613B1/en unknown
- 2016-08-12 CL CL2016002043A patent/CL2016002043A1/es unknown
- 2016-09-01 ZA ZA2016/06077A patent/ZA201606077B/en unknown
- 2016-09-14 EC ECIEPI201674207A patent/ECSP16074207A/es unknown
-
2018
- 2018-05-14 US US15/979,069 patent/US10273225B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20170245A1 (es) | Pirazinas moduladoras de gpr 6 | |
| PE20141202A1 (es) | Compuesto de ciclopropanoamina | |
| PE20200292A1 (es) | Compuestos de heteroarilo biciclicos 6-6 fusionados y su uso como inhibidores de lats | |
| PE20220597A1 (es) | Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos | |
| PE20191478A1 (es) | Compuestos moduladores del receptor de hidorcarburos de arilo (ahr) | |
| PE20151781A1 (es) | Piridonamidas como moduladores de canales de sodio | |
| PE20191479A1 (es) | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) | |
| PE20170268A1 (es) | Compuestos de heteroarilo para la inhibicion de cinasa | |
| PE20161443A1 (es) | Compuestos | |
| PE20240221A1 (es) | Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos | |
| EA202091477A1 (ru) | Замещенные соединения простых индольных эфиров | |
| GEP201706608B (en) | 1 - arylcarbonyl - 4 - oxy – piperidine compounds useful for the treatment of neurodegenerative diseases | |
| AR061644A1 (es) | Derivados de benzofurano | |
| PE20181144A1 (es) | Derivados de heteroarilo como inhibidores de parp | |
| PE20171623A1 (es) | Agentes inmunomoduladores | |
| PE20110397A1 (es) | Compuestos que modulan selectivamente el receptor cb2 | |
| PE20141791A1 (es) | Compuestos de enediino, conjugados de los mismos y sus usos y metodos | |
| PE20161444A1 (es) | 1,2-ciclopentanos sustituidos como antagonistas del receptor de orexina | |
| PE20181015A1 (es) | 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
| CY1120325T1 (el) | Τρικυκλικες ετεροκυκλικες ενωσεις ως αναστολεις φωσφοϊνοσιτιδιου 3-κινασης | |
| PE20180355A1 (es) | Desacetoxitubulisina h y analogos de esta | |
| CO6160326A2 (es) | Derivados de pirrolidin-2-ona como moduladores del receptor de androgeno | |
| EA201590228A1 (ru) | Антагонисты 5-ht3 рецептора | |
| PE20140703A1 (es) | Derivados de heteroarilo como moduladores de nachr alfa 7 | |
| PE20191082A1 (es) | Inhibidores de la tirosina quinasa de bruton |